Navigation Links
Scripps Research cancer biology department awarded more than $8 million in new research grants
Date:4/22/2009

"The fact that our scientists have been so successful in winning these awards speaks volumes for the high caliber of research being performed at Scripps Florida and in the Department of Cancer Biology," said John Cleveland, Ph.D., chairman of the department, which is located on the Jupiter, Florida campus of TSRI. "During these times when funding is so tight, to have so many of our investigators be given awards is remarkable."

The grants, from the NIH and the Department of Defense, included the following awards:

  • Howard Petrie, Ph.D., received a pair of grants from the NIH worth a total of $4.3 million dollars over the next five years.

    Petrie's first grant (approximately $2.4 million) studies how a gene known as Notch3 that controls the development and production of T lymphocytes, white blood cells whose development starts in the bone marrow but is completed in the thymus, and then attack infectious agents as well as cancer cells. Petrie and his colleagues have discovered that inactivation of Notch3 results in an accelerated, age-related decline in the ability of the bone marrow to replenish T lymphocytes; Notch3 has also been implicated in another age-related degenerative disorder, relating to stroke. Petrie's goal is to understand how Notch3 normally prevents this aging of the immune system, and how Notch3 functions in general in blood cells as well as other tissue types.

The second grant (approximately $1.9 million) will support Petrie's work understanding regrowth of the thymus in adults and the elderly. Decreases in T cell immunity are a direct consequence of age-related degeneration of the thymus, a process that has been linked to premature aging of stromal cells (which form the supportive framework of the thymus and other organs). Using an experimental model of thymus regrowth, Dr. Petrie and his colleagues will seek to identify the changes in gene expression that occur after induction of regrowth, and to recapitulate these through pharmaceutical approaches for thymus regeneration therapy.

  • Cleveland received a five-year grant (approximately $2.1 million) from NIH/NCI to study the regulation and role of the enzyme ornithine decarboxylase (Odc). This enzyme plays key roles in cancer and is directly regulated by cancer-causing Myc oncoproteins and also by mutated Ras oncogenes, which together are activated in more than 80 percent of all human tumors. This new study focuses on defining the various roles of Odc in regulating the development of lymphoma, lung, and breast cancer, and determining how Odc regulates the proliferative response induced by oncogenes. Cleveland hopes that these studies will reveal new targets for cancer prevention and treatment.

  • Jun-Li Luo, Ph.D., received a three-year grant (approximately $430,000) from the U.S. Department of Defense to study the interaction between cancer stem cells and immune/inflammatory cells during the growth and progression of prostate cancer. In a study published in a 2004 issue of the journal Cancer Cell, Luo and colleagues developed a novel strategy to fight the disease, turning the body's inflammatory response, which under normal circumstances encourages tumor growth, into a cancer-killing machine. In 2007 Luo published an article in Nature that established links between the nuclear factor NF-κB and the spread of prostate cancer in animal models.

In addition to these funds, investigators in the Department of Cancer Biology were awarded a four-year grant (approximately $1.6 million) from NIH's National Institute of General Medical Science to study the structural dynamics of vinculin, a cytoskeletal protein that plays key roles in controlling cell-cell and cell-matrix adhesion complexes, as well as cell migration and cancer metastasis.


'/>"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Related medicine news :

1. Scripps research scientists model 3D structures of proteins that control human clock
2. Scripps Health Selects Allscripts for Electronic Health Record
3. Scripps research scientists engineer new type of vaccination that provides instant immunity
4. Scripps research scientists develop general-purpose method for detecting trace chemicals
5. Team led by Scripps Scientists increases understanding of two types of blindness
6. KRAUSE, KALFAYAN, BENINK & SLAVENS, LLP, Announces Filing a Class Action Lawsuit Against Scripps Health, et al.
7. Scripps Health Enhances Employee Wellness Program With Home Testing Solutions From BioIQ
8. Scripps Research Institute and IAVI launch worlds first dedicated HIV neutralizing antibody center
9. Scripps Translational Science Institute Contributes to Discovery of Predisposition Gene for Childhood Cancer
10. Scripps research team unravels new cellular repair mechanism
11. Scripps Research scientists find seizure drug reverses cellular effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Utah (PRWEB) , ... February 28, 2017 , ... ... held Overl.ai Inc., a healthcare automation intelligence company based in New York. , ... is ensuring the provider’s workflow remains unaltered. Those two fundamental reasons are the ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... and overall body strength, which often leads to a host of health issues, ... of the American Geriatrics Society discovered that good overall muscle strength in ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear ... work for a company involved in the underground testing of nuclear weapons. Years later, ... Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... Morristown, New Jersey (PRWEB) , ... February 27, 2017 , ... ... the highest cancer rates, among all types and genders. And the need for advanced ... led by RWJ and its top-rated cancer care program, in collaboration with their non-profit ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... LONDON , Feb. 27, 2017 This ... understand Teva and its partnering interests and activities since ... Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
(Date:2/28/2017)... 2017 Research and Markets has announced ... 2014-2025" report to their offering. ... The global digestive enzyme ... 2025. Growing consumer awareness regarding the severity of digestive disorders ... stimulate industry growth over the forecast period. The increasing incidence ...
(Date:2/28/2017)... ... Research and Markets has announced the addition of the "Orthobiologics ... The global orthobiologics market is expected to reach USD 10.2 ... predominantly driven by the increasing orthopedic disease and musculoskeletal disease burden ... of orthobiologics are presumed to accelerate the market demand over the ...
Breaking Medicine Technology: